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Dear editor,
We read with interest the paper presented by Saeed
et al [1], ‘The early identification of disease progres-
sion in patients with suspected infection presenting to
the emergency department: a multi-centre derivation
and validation study’. We retrospectively applied
the cut-offs for mid-regional pro-adrenomedullin
(MR-proADM) and C-reactive protein (CRP)
derived in this study to the cohort used in our
paper, ‘Can mid-regional pro-adrenomedullin (MR-proADM)
increase the prognostic accuracy of NEWS in pre-
dicting deterioration in patients admitted to hospital
with mild to moderately severe illness? A prospective
single-centre observational study’ [2] to see if we
could replicate the sensitivity and specificity obtained
for predicting avoidance of hospitalisation, defined as
a discharge to community care within 24 h of
presentation.
Our original study was a prospective observa-
tional cohort study [2]. Between September and
December 2015, 300 patients who attended the
Medical Assessment Unit at the Royal Victoria
Infirmary, Newcastle, were enrolled. Patients were
included whose National Early Warning Score
(NEWS) was greater than or equal to 2 and less
than or equal to 5. Those admitted for purely so-
cial reasons, were to receive only palliative care
or had been admitted due to self-harm or over-
dose were excluded.
One hundred twenty-three patients had, at
discharge, a diagnosis of an infection. Twenty
(16.3%) of these were discharged within 24 h. An
MR-proADM of less than 0.87 nmol L−1 gave a sen-
sitivity of 60% (44–71% 95%CI) and a specificity of
60% (53–66% CI) for discharge within 24 h. See
Table 1 for comparison to Saeed et al. [1].
We have failed to replicate the utility suggested
in the paper by Saeed et al. for MR-proADM
predicting hospitalisation avoidance. However, the
cohort here differs from that of Saeed et al. in
many respects. Patients who attended the Medical
Assessment Unit had already been assessed by ei-
ther an emergency department physician or a
general practitioner and have been considered to
be likely to require hospitalisation. Furthermore,
our study population was limited to those with
NEWS score between 2 and 5 compared to the un-
selected cohort of Saeed et al. However, with a
median NEWS of 4, their cohort’s NEWS may not
differ greatly from ours.
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This demonstrates that other patient characteristics
and the stage in the patient pathway are likely to be
important when choosing how to implement this
biomarker in aiding decisions about avoiding hospitalisa-
tion. Earlier use of the MR-proADM in unselected pa-
tients in an ED setting may help select patients for early
discharge.
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Table 1 Test accuracy for prediction of hospitalisation
avoidance by Saeed et al. and from our data
Graziadio et al [2] Saeed et al [1]
MR-proADM Sensitivity 0.60 [0.44–0.71] 0.75 [0.72–0.78]
Specificity 0.60 [0.53–0.66] 0.80 [0.74–0.84]
LR+ 1.24 [0.82–1.86] 3.69 [2.90–4.71]
LR− 0.78 [0.44–1.37] 0.31 [0.27–0.35]
PPV 0.19 [0.14–0.87] 0.93 [0.91–0.95]
NPV 0.87 [0.79–0.92] 0.48 [0.43–0.52]
CRP Sensitivity 0.85 [0.62–0.97] 0.42 [0.39–0.45]
Specificity 0.21 [0.13–0.30] 0.77 [0.72–0.82]
LR+ 1.07 [0.87–1.32] 1.84 [1.45–2.33]
LR− 0.72 [0.24–2.19] 0.75 [0.69–0.82]
PPV 0.18 [0.15–0.21] 0.87 [0.83–0.89]
NPV 0.88 [0.70–0.96] 0.27 [0.24–0.31]
MR-proADM mid-regional pro-adrenomedullin, CRP C-reactive protein, PPV
positive predictive value, NPV negative predictive value, LR+ positive likelihood
ratio, LR− negative likelihood ratio
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